|
See related Iressa film-coated tab information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
DKSH |
|
Contents |
Gefitinib |
|
Indications |
1st-line treatment of patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR TK. Treatment of patients w/ locally advanced or metastatic NSCLC who have received previous chemotherapy.
Click to view Iressa detailed prescribing infomation |
|
Dosage |
1 tab once a day.
Click to view Iressa detailed prescribing infomation |
|
Overdosage |
View Iressa overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Tab may be dispersed in ½ glass of non-carbonated drinking water. No other liqd should be used. Drop the tab in water & w/o crushing it, stir until dispersed (approx 10 min). Drink the liqd immediately. Rinse the glass w/ another ½ glass of water & drink. The liqd may also be admin via a nasogastric tube.). |
|
Contraindications |
[Click for Iressa detailed prescribing infomation] |
|
Special Precautions |
Interstitial lung disease (ILD). Perform periodic liver function tests. Monitor patients taking warfarin for changes in prothrombin time or INR. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescents.
Click to view Iressa detailed prescribing infomation |
|
Adverse Drug Reactions |
Diarrhea, nausea, vomiting, stomatitis; elevations in ALT, AST, total bilirubin, blood creatinine; anorexia, skin reactions (eg rash, acne, dry skin, pruritus), asthenia, epistaxis, haematuria, proteinuria, nail & eye disorders, alopecia, pyrexia, dehydration, dry mouth, ILD.
View ADR Monitoring Form |
|
Drug Interactions |
Reduced efficacy w/ phenytoin, carbamazepine, rifampicin, barbiturates & St. John's wort. Increased mean AUC w/ itraconazole. Reduced mean AUC w/ ranitidine. Increased INR &/or bleeding events w/ warfarin.
View more drug interactions with Iressa |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Iressa storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Iressa description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Iressa mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Iressa film-coated tablet |
|
Iressa 250 mg x 3 x 10's |
 |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
DKSH
|
|
|
|
